Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages 317-329 , April 2008

The benefits of early androgen blockade

  • Paul D. Maroni, MD (Assistant Professor, Department of Surgery (Urology))

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 303 724 2712; Fax: +1 303 724 2818.
    • ,
  • E. David Crawford, MD (Professor of Surgery, Chief of Urologic Oncology, Department of Radiation Oncology)

References 

  1. Huggins C, Hodges CU. Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research. 1941;1
  2. Nesbit RM, Baum WC. Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. The Journal of the American Medical Association. 1950;143
  3. Alam N, Darling G, Evans WK, et al. Adjuvant chemotherapy for completely resected non-small cell lung cancer: a systematic review. Critical Reviews in Oncology/Hematology. 2006;58:146–155
  4. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. Journal of Clinical Oncology. 2004;22:1797–1806
  5. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials.. Lancet. 1998;352:930–942
  6. LHRH-agonists in Early Breast Cancer Overview Group . Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369:1711–1723
  7. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials.. Lancet. 1998;351:1451–1467
  8. Wilt T, Nair B, MacDonald R, et al. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database of Systematic Reviews. 2001;(4):
  9. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology Practice Guideline. Journal of Clinical Oncology. 2007;25:1596–1605
  10. Seidenfeld J, Samson DJ, Aronson N, et al. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Bethesda: United States Public Health Service; 1999;
  11. Kumar S, Shelley M, Harrison C, et al. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database of Systematic Reviews. 2006;(4):
  12. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncology. 2006;7:472–479
  13. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103–108
  14. Pilepich MV, Winter K, Lawton C, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31. International Journal of Radiation Oncology, Biology, Physics. 2005;61(5):1285–1290
  15. D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. Journal of the American Medical Association. 2004;292:821–827
  16. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. The Journal of the American Medical Association. 1998;280(11):969–974
  17. McLeod DG, Iversen P, See WA, et al. Bicalutamide 150mg plus standard care alone for early prostate cancer. BJU International. 2005;97:247–254
  18. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials.. Lancet. 2000;355:1491–1498
  19. Blackard CE, Byar DP, Jordan WP. Orchiectomy for advanced prostatic carcinoma: A reevaluation. Urology. 1973;1
  20. Byar DP. The veterans administration cooperative urological research group's studies of cancer of the prostate. Cancer. 1973;32
  21. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group Studies. NCI Monographs. 1988;7:165
  22. Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council. British Journal of Urology. 1997;79
  23. Schroder FH, Kurth KH, Fossa SD, et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846-a phase III study. Journal of Urology. 2004;172:923–927
  24. Sandler HM, Eisenberger MA. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. Journal of Urology. 2007;178:S20–S24
  25. Freedland SJ, Moul JW. Prostate specific antigen recurrence after definitive therapy. Journal of Urology. 2007;177:1985–1991
  26. Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. Journal of Urology. 2004;171:1141–1147
  27. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. Journal of the American Medical Association. 1999;281:1591–1597
  28. Freedland SJ, Humphreys EB, Mangold LA, et al. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. Journal of Urology. 2006;178:1404–1408
  29. Tenenholz TC, Shields C, Ramesh VR, et al. Survival benefit for early hormone ablation in biochemically recurrent prostate cancer. Urologic Oncology: Seminars and Original Investigations. 2007;25:101–109
  30. Shipley WU, DeSilvio M, Pilepich MV, et al. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: a secondary analysis of RTOG protocol 86-10. International Journal of Radiation Oncology, Biology, Physics. 2006;64:1162–1167
  31. Schulman CC, Debruyne FMJ, Foster G, et al. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Urology. 2000;38(6):706–713
  32. Klotz LH, Goldenberg SL, Jewett MAS, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. Journal of Urology. 2003;170(3):791–794
  33. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics. 2001;50:1243–1252
  34. McLeod DG, See WA, Klimberg I, et al. The bicalutamide 150mg Early Prostate Cancer Program: findings of the North American trial at 7.7-year median followup. Journal of Urology. 2006;176:75–80
  35. Wirth MP, Tyearrell CJ, Delaere K, et al. Bicalutamide (Casodex) 150mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer trial 24 at a median 7 years' follow-up. Prostate Cancer and Prostatic Diseases. 2007;10:87–93
  36. Daniell HW. Osteoporosis after ochiectomy for prostate cancer. Journal of Urology. 1997;157:439–444
  37. Eriksson S, Eriksson A, Stege R, et al. Bone mineral density in patients with prostatic cancer treated with orchiectomy and with estrogens. Calcified Tissue International. 1995;57:97–99
  38. Saad F, Clarke N, Colombel M. Natural history and treatment of bone complications in prostate cancer. European Urology. 2006;49:429–440
  39. Basaria S, Lieb J, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clinical Endocrinology. 2002;56:779–786
  40. Morote J, Orsola A, Abascal JM, et al. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. Journal of Urology. 2006;175:1679–1683
  41. Malcolm JB, Derweesh IH, Kincade MC, et al. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. The Canadian Journal of Urology. 2007;14(3):3551–3559
  42. Smith MR, Goode M, Zietman AL, et al. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Journal of Clinical Oncology. 2004;22(13):2546–2553
  43. Greenspan SL, Nelson JB, Trump D, et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Annals of Internal Medicine. 2007;146:416–424
  44. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. Journal of Clinical Oncology. 2007;25:1038–1042
  45. Mason MD, Sydes M, Glaholm J, et al. Oral sodium clodronate for nonmetastatic prostate cancer – Results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). Journal of the National Cancer Institute. 2007;99:765–776
  46. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology. 2006;24:4448–4456
  47. Basaria S, Muller DC, Carducci M, et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106:581–588

PII: S1521-690X(08)00014-6

doi: 10.1016/j.beem.2008.01.013

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages 317-329 , April 2008

Article Tools

* Image Usage & Resolution